research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-28. Numbers and descriptions here follow the published literature rather than marketing material.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Advising, diagnosing, interpreting, and treating patients Advising health and social care professionals in the diagnosis and treatment of patients Researching the science, technology, and practise used in healthcare to innovate and improve services Designing, building, and operating technology for diagnosing and treating patients Ensuring the safety and reliability of tests and equipment used in healthcare Trainee clinical scientist posts are advertised nationally, usually between November and February on the Clinical scientists recruitment webpages where application forms may be obtained and electronic submission of applications can be made. These posts are for the approved pre-registration training programme, designed to prepare entrants for higher professional qualifications, further clinical training and eventual Consultant responsibility. Clinical scientist training involves enrolment of graduates (first or second class honours degree or better is essential due to the high competition for limited training places) into an intensive three-year training scheme leading to certification and eventual registration before starting the higher career structure.
A pharmacologically important aspect of the contraction-reducing properties of ingested salvinorin A on gut tissue is that it is only pharmacologically active on inflamed and not normal tissue, thus reducing possible side-effects.
== History of discovery == This analgesic activity of M6G (in animals) was first noted by Yoshimura. Subsequent work at St Bartholomew's Hospital, London in the 1980s, using a sensitive and specific high-performance liquid chromatography assay, accurately defined for the first time the metabolism of morphine, and the abundance of this metabolite (along with morphine-3-glucuronide, considered an inactive metabolite). It was postulated that kidney impairment would result in accumulation of the kidney-excreted active agent M6G, leading to potentially fatal toxicity such as respiratory depression. The frequent use of morphine in critically ill patients, and the common occurrence of kidney failure in this group implied that M6G accumulation could be a common, but previously unanticipated problem. The first studies demonstrated massive levels of M6G in 3 patients with kidney failure, which resolved as kidney function returned. Accumulation of M3G and M6G also decreased with return of kidney function after kidney transplantation. A key step in defining the importance of M6G in humans came in 1992 when the substance was artificially synthesised and administered to patients with pain, the majority of whom described pain relief.
Thrombocytopenia : The drug is contraindicated in patients with platelet counts of less than 100,000 per μL because no clinical experience exists regarding such patients. Chronic kidney disease : Eptifibatide undergoes kidney elimination. In such patients with chronic kidney disease where a glycoprotein IIb/IIIa inhibitor is likely to provide benefit, Abciximab (trade name: Reopro) is an alternative medication. Current bleeding tendencies or abnormally prolonged coagulation parameters observed within 30 days before starting therapy with eptifibatide is intended. Coagulation parameters such as ACT, aPTT, TT, and PT should be followed closely during therapy and afterwards. Allergy to eptifibatide and/or other ingredients. Severe, uncontrolled hypertension. Pregnancy : No experience exists. Pregnant patients should be treated only when clearly needed. Lactation : No human data exists. Breast-feeding should be avoided during treatment in order to prevent damage to the newborn. Geriatric patients : No differences in side effects compared with younger patients have been seen. Nevertheless, geriatric patients should be very closely observed for bleeding and other side-effects. Pediatric patients : Eptifibatide is not indicated in patients below 18 years of age, because no experience exists.
Sources: en.wikipedia.org
To demonstrate just how deadly this species is, an estimate was made on the number of mice and adult human fatalities it is capable of causing in a single bite that yields the maximum dose of 400 mg. Based on the study by Ernst and Zug et al. 1996, which listed the LD50 of the coastal taipan at 0.106 mg SC and a venom yield of 400 mg, this would be sufficient to kill 208,019 mice and 59 adult humans in a single bite that delivers 400 mg of venom. The venom apparatus of this species is well developed. The fangs are the longest of any Australian elapid snake, being up to 1.2 cm (0.5 in) long, and are able to be brought forward slightly when a strike is contemplated. Coastal taipans can inject large amounts of highly toxic venom deep into the tissue. Its venom contains primarily taicatoxin, a highly potent neurotoxin known to cause hemolytic and coagulopathic reactions. The venom affects the nervous system and the blood's ability to clot, and bite victims may experience headache, nausea and vomiting, collapse, convulsions (especially in children), paralysis, internal bleeding, myolysis (destruction of muscle tissue) and kidney damage. In a single study done in Papua New Guinea, 166 patients with enzyme immunoassay-proven bites by Papuan taipans (Oxyuranus scutellatus canni) were studied in Port Moresby, Papua New Guinea. Of the 166 bite victims, 139 (84%) showed clinical evidence of envenoming: local signs were trivial, but the majority developed hemostatic disorders and neurotoxicity.
Duffy announced later that year that work would begin in 2027 and would cost $7 billion, and in May 2026 Amtrak selected out of three finalists a joint venture of Skanska and Halmar International as developer and Vishaan Chakrabarti's Practice for Architecture and Urbanism (PAU) as lead design architect. The approved plan would keep Madison Square Garden in place and rebuild the passenger facilities beneath it. In June 2026, Amtrak and Penn Transformation Partners released renderings for an approximately $8 billion redesign of Penn Station that would retain Madison Square Garden while creating a larger, light-filled station inspired by the original Pennsylvania Station. Later that month, a pre-development agreement (PDA) was finalized, with the project estimated to break ground by the end of 2027. Amtrak also offered to re-add the MTA as a partner in the station's reconstruction, but the MTA declined.
One of the earliest successes of hydroponics occurred on Wake Island, a rocky atoll in the Pacific Ocean used as a refueling stop for Pan American Airlines. Hydroponics was used there in the 1930s to grow vegetables for the passengers. Hydroponics was a necessity on Wake Island because there was no soil, and it was prohibitively expensive to airlift in fresh vegetables. From 1943 to 1946, Daniel I. Arnon served as a major in the United States Army and used his prior expertise with plant nutrition to feed troops stationed on barren Ponape Island in the western Pacific by growing crops in gravel and nutrient-rich water because there was no arable land available. In the 1960s, Allen Cooper of England developed the nutrient film technique. The Land Pavilion at Walt Disney World's EPCOT Center opened in 1982 and prominently features a variety of hydroponic techniques. In recent decades, NASA has done extensive hydroponic research for its Controlled Ecological Life Support System (CELSS) and Advanced Life Support (ALS) programs. Hydroponics research mimicking space environments will need further study for different gravity environments, for example u-gravity in Low Earth Orbit, 1/6 g on the Moon, and 1/3 g on Mars. Ray Wheeler, a plant physiologist at Kennedy Space Center's Space Life Science Lab, believes that hydroponics will allow water and nutrient recycling needed for space travel and eventual bioregenerative life support systems where plants are used to produce oxygen and food, while removing carbon dioxide.
== Naming conventions == Before reunification, Germany was divided between the Bundesrepublik Deutschland (Federal Republic of Germany; commonly known as West Germany) and the Deutsche Demokratische Republik (DDR; German Democratic Republic; commonly known as East Germany). Reunification was achieved by accession (Beitritt) of the German Democratic Republic to the Federal Republic of Germany, so Bundesrepublik Deutschland became the official name of reunified Germany. In East Germany, the terms Westdeutschland (West Germany) or westdeutsche Bundesrepublik (West German Federal Republic) were preferred during the 1950s and 1960s. This changed under its constitutional amendment in 1974, when the idea of a single German nation was abandoned by East Germany. As a result, it officially considered West Germans and West Berliners as foreigners. The initialism BRD (FRG in English) began to prevail in East German usage in the early 1970s, beginning in the newspaper Neues Deutschland. Other Eastern Bloc nations soon followed suit. In 1965, the West German Federal Minister of All-German Affairs, Erich Mende, had issued the "Directives for the Appellation of Germany", recommending avoiding the initialism BRD. On 31 May 1974, the heads of West German federal and state governments recommended always using the full name in official publications. From then on, West German sources avoided the abbreviated form, with the exception of left-leaning organisations which embraced it.
==== MeSH D12.776.964.775.350 – gene products, gag (gene) ==== MeSH D12.776.964.775.350.320 – fusion proteins, gag-onc MeSH D12.776.964.775.350.320.700 – oncogene protein p65(gag-jun) MeSH D12.776.964.775.350.325 – fusion proteins, gag-pol MeSH D12.776.964.775.350.400 – hiv core protein p24
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.